Kimer Med is a biotech start-up, located in Nelson, New Zealand.
We are developing the next-generation version of a broad-spectrum antiviral drug called DRACO. Work on DRACO was first published in 2011, based on research done at MIT’s Lincoln Laboratory, which found it to be effective against 15 different viruses in cell cultures, and against Influenza H1N1 in mice.
We have just started a crowdfunding campaign for development of this antiviral. Our fundraising goal is NZD $50,000 (appx USD $33,000).
Proceeds from the campaign will be used to fund testing against several viruses of interest. A unique feature of the campaign is that you can influence the company’s testing priorities, by sponsoring a virus of your choice. The viruses available for sponsorship include HIV, Hepatitis B, Herpes Simplex 1 and 2, Human Papilloma Virus (HPV), Influenza B, SARS-CoV-2, Epstein-Barr Virus (EBV), Cytomegalovirus (CMV), Rabies (dogs), Porcine Reproductive and Respiratory Syndrome Virus (pigs), and Feline Infectious Peritonitis (cats).
In addition to treating diseases caused by viruses, we are also pursuing a potential rejuvenation therapy, based on the fact that certain viruses, such as CMV, can cause immunosenescence (aging of the immune system).
We have already begun fabrication of the first version of the compound, and we expect to begin testing before the end of the year.
https://donate.kimer...g-viral-disease
